CME Group Inc.

🇺🇸NASDAQ Global Select
Back to all articles
CME Group Inc. stock analysis CME overview
Somewhat Bullish +35

CME Group Inc. Class A

📊 CME Group stock is trading mid-range with a 52-week range and above its 200-day moving average.

📉 Shares have fallen $3.63 or 1.21% since the last market close, though after-hours trading saw a $0.70 rebound.

🏢 The company operates global derivatives exchanges offering futures and options across rates, equities, FX, energy, agriculture, and metals.

📈 Morgan Stanley raised its price target to $362, while TD Cowen increased its target to $340.

💰 Barclays lifted its price target to $344 and reaffirmed a Hold rating on CME Group stock.

⚖️ Analyst opinions remain mixed, with Goldman Sachs maintaining a Sell rating and Argus downgrading CME to Hold citing muted growth.

📈 Q1 international Annualized Daily Volume (ADV) rose 30% year-over-year, reaching 11.4 million contracts.

🌱 Energy complex hit an all-time ADV record of 8.3 million contracts in recent trading.

💹 Total revenue grew 6.37% year-over-year, with net income up 14.58% for the same period.

📊 Earnings per share reached $11.16 annually and $3.24 in the fourth quarter, reflecting significant growth.

⚠️ Recent issues were reported with the Globex platform affecting metals and natural gas markets.

💻 CME Group has recently expanded its offerings by launching futures on Avalanche and Sui blockchain assets.

🔍 Regulatory bodies like the CFTC continue to focus on market integrity, particularly regarding prediction markets in sports.

📉 Regional bank ETFs are underperforming, yet CME remains a key player within the Finance sector.

🌐 The company is headquartered in Chicago and maintains operations as a central counterparty clearing provider.

Bullish Signals
  • CME Group shares have risen $0.70 in after-hours trading, demonstrating resilience despite a intraday decline.
  • Morgan Stanley raised its price target to $362, signaling strong bullish sentiment on the stock.
  • TD Cowen increased CME's price target from $328 to $340, reflecting growing confidence in future performance.
  • Barclays raised its price target to $344, indicating positive outlook for the company.
  • CME Group achieved a record international ADV of 11.4M contracts in Q1, representing a 30% increase year-over-year.
  • March ADV reached 41.1M contracts, highlighting robust trading volume across global benchmark products.
  • Energy complex hit an all-time ADV record of 8.3M contracts, underscoring strong activity in key commodity markets.
  • February ADV was up 14% year over year, showing consistent growth in futures and options market participation.
  • Total revenue increased 6.37% since last year with EPS growing 15.38%, demonstrating solid financial performance.
  • Net income jumped 14.58% year-over-year, confirming improved profitability driven by operational leverage.
  • CME Group launched new futures contracts for Avalanche and Sui, expanding its digital asset offerings in a strategic move.
Risk Factors
  • CME Group has received a 'Sell' rating reaffirmed by Goldman Sachs, indicating significant analyst skepticism about the stock's prospects.
  • Argus Capital downgraded CME Group to Hold from Buy, citing concerns over muted growth in equity, metals, and crypto segments.
  • The stock is trading in the middle of its 52-week range, which often signals consolidation or lack of upward momentum rather than strong performance.
  • Analyst sentiments on CME Group are mixed, creating uncertainty around its valuation and future direction compared to peers.
  • CME Group is investigating issues with Globex metals and natural gas markets, exposing potential operational risks in key product lines.
Full Analysis
CME Group Inc., a derivatives marketplace operator based in Chicago, Illinois, is currently trading within its 52-week range and above its 200-day simple moving average. The stock has seen mixed movement recently, with shares decreasing $3.63, or 1.21%, since the last market close before rising $0.70 in after-hours trading. Founded in 1898, the company operates across interest rates, equity indexes, foreign exchange, energy, agricultural commodities, and metals through platforms like CME Globex, BrokerTec, and EBS, while also managing central counterparty clearing via CME Clearing. Financially, the company is categorized as large-cap with a market capitalization between $10 billion and $200 billion. Analyst sentiment regarding CME Group shares has been inconsistent across major investment banks. Morgan Stanley raised its price target to $362 from $340 and issued a buy rating, while TD Cowen elevated its target to $344 from $328. Barclays increased its price target to $344 from $312 but maintained a hold rating, and Keefe Bruyette reinstated a market perform rating after previously holding. Conversely, Goldman Sachs affirmed its sell rating, and Erste Group upgraded the stock from hold to buy. Argus, however, downgraded CME to hold citing concerns over muted growth in equity, metals, and crypto sectors. Recent financial performance highlights include significant increases in revenue and income. Total revenue grew by 6.37% year-over-year and 7.23% quarter-over-quarter, while net income rose 14.58% annually and 30.08% quarter-over-quarter. Earnings per share stood at $11.16 for the year with a quarterly figure of $3.24, representing a 15.38% annual increase and a 30.34% quarterly rise. Trading volumes have also shown robustness, with Q1 international advanced volume reaching 11.4 million contracts, a 30% increase, and March ADV recording 41.1 million contracts with February ADV up 14% year over year. Additionally, the company achieved a record all-time daily average volume of 8.3 million contracts in its energy complex.